IL17A and tuberculosis: Furthermore, in vivo experiments in our study demonstrated that ADMSCs‐EVs derived miR‐150‐5p inhibited CVF, reduced the levels of inflammatory factors (TNF‐α, IL‐6 and IL‐17), hepatic injury and function‐associated indicators (ALT, AST and TB).